Direct comparison of doses did not show evidence of dose dependence for blood pressure-lowering for any of the other thiazides for which RCT data were available : bendrofluazide , chlorthalidone , cyclopenthiazide , metolazone or indapamide .
This is based on an informal indirect comparison of results observed in other Cochrane review s on ACE inhibitors , ARBs and renin inhibitors compared with placebo , which used similar inclusion /exclusion criteria to the present review .Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides .
These effects were dose-related and were least for hydrochlorothiazide .
Chlorthalidone increased serum glucose but the evidence was unclear for other thiazides .
This systematic review shows that hydrochlorothiazide has a dose-related blood pressure-lowering effect .
Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides
BACKGROUND Hypertension is a modifiable cardiovascular risk factor .
Although it is established that low-dose thiazides reduce mortality as well as cardiovascular morbidity , the dose-related effect of thiazides in decreasing blood pressure has not been subject to a rigorous systematic review .
It is not known whether individual drugs within the thiazide diuretic class differ in their blood pressure-lowering effects and adverse effects .
OBJECTIVES To determine the dose-related decrease in systolic and /or diastolic blood pressure due to thiazide diuretics compared with placebo control in the treatment of patients with primary hypertension .
Secondary outcomes included the dose-related adverse events leading to patient withdrawal and adverse biochemical effects on serum potassium , uric acid , creatinine , glucose and lipids .
Efficacious response with lower dose indapamide therapy in the treatment of elderly patients with mild to moderate hypertension.
A low dose ( 1.25 mg ) of indapamide ( Lozol , Rhône-Poulenc Rorer Pharmaceuticals , Collegeville , PA ) was evaluated in 222 elderly patients ( > or = 50 years ) with mild to moderate essential hypertension in a multicenter , r and omized , double-blind , parallel-group clinical trial . A 4-week single-blind placebo washout period was followed by an 8-week double-blind treatment period . Patients were r and omized to receive indapamide 1.25 mg/day or to receive placebo . The primary efficacy variable was the mean change in sitting diastolic blood pressure from baseline to week 8 . Eighty-one patients in the indapamide group ( 73 % ) and 87 patients in the placebo group ( 78 % ) completed the 8 weeks of double-blind therapy . Therapy with 1.25 mg of indapamide produced greater reductions compared with placebo in sitting diastolic blood pressure after 8 weeks of therapy , with statistical significance ( P < or = 0.0015 ) seen after only 2 weeks of therapy and continuing throughout the 8 weeks . All secondary efficacy measures ( sitting systolic blood pressure , st and ing systolic and diastolic blood pressures , and > or = 10 mm Hg decrease or final value of < or = 90 mm Hg in sitting diastolic blood pressure ) also showed superior ( P < or = 0.0014 ) improvement in the indapamide group compared with placebo after 8 weeks of double-blind treatment . During the 8-week double-blind treatment period , incidence rates for all adverse events and for drug-related adverse events were similar between the two treatment groups . ( ABSTRACT TRUNCATED AT 250 WORDS
Direct comparison of doses did not show evidence of dose dependence for blood pressure-lowering for any of the other thiazides for which RCT data were available : bendrofluazide , chlorthalidone , cyclopenthiazide , metolazone or indapamide .
This is based on an informal indirect comparison of results observed in other Cochrane review s on ACE inhibitors , ARBs and renin inhibitors compared with placebo , which used similar inclusion /exclusion criteria to the present review .Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides .
These effects were dose-related and were least for hydrochlorothiazide .
Chlorthalidone increased serum glucose but the evidence was unclear for other thiazides .
This systematic review shows that hydrochlorothiazide has a dose-related blood pressure-lowering effect .
Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides
BACKGROUND Hypertension is a modifiable cardiovascular risk factor .
Although it is established that low-dose thiazides reduce mortality as well as cardiovascular morbidity , the dose-related effect of thiazides in decreasing blood pressure has not been subject to a rigorous systematic review .
It is not known whether individual drugs within the thiazide diuretic class differ in their blood pressure-lowering effects and adverse effects .
OBJECTIVES To determine the dose-related decrease in systolic and /or diastolic blood pressure due to thiazide diuretics compared with placebo control in the treatment of patients with primary hypertension .
Secondary outcomes included the dose-related adverse events leading to patient withdrawal and adverse biochemical effects on serum potassium , uric acid , creatinine , glucose and lipids .